Jutta Deckert

Company: Iksuda Therapeutics

Job title: Vice President, Research & Development

Seminars:

Chair’s Closing Remarks 3:00 pm

Read more

day: Scientific Program Day Two

Comparing Toxicity Tolerability From Payloads in Non-Human Primates & Humans to Improve the Translatability of the ADC Candidate 9:00 am

Comparing inhibitors in NHPs vs humans to assess toxicities in different patients Evaluating why there is lower tolerability in the clinic compared to NHP models while considering mediation and expression of tumour targets and payload distribution in tissues Investigating how we can better predict on target tumour toxicity from NHPs to humans from inhibitors by…Read more

day: Scientific Program Day One

Chairs Opening Remarks 8:25 am

Read more

day: Scientific Program Day Two

Evaluating Emerging ADC Designs to Understand Their Impact on Safety Profiles – Where Are We Headed? 11:00 am

Reviewing new ADC designs and how they may lead to improved safety profiles such as reduced neutropenia and GI toxicities Discussing the challenges of preclinical to clinical translation of safety profiles – how can we design ADCs to be safer based on preclinical evaluation? Exploring how ADC design innovations will support future differentiation and improve…Read more

day: Scientific Program Day Two

A Hanson Wade Group Company

© Copyright 2025 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.